Psilocybin Amorphous Formulation for Stability and Flow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Psilocybin is challenging to formulate due to its physical characteristics and chemical instability, leading to poor flow properties and stability issues in pharmaceutical compositions, particularly in solid dosage forms, which affects content uniformity and potency during storage.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of psilocybin and pharmaceutically acceptable excipients, where the psilocybin is stabilized through direct mixing and encapsulation, maintaining potency and content uniformity even under harsh storage conditions, such as 40°C and 75% relative humidity, with specific crystalline forms like Polymorph A ensuring chemical purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If crystalline psilocybin is used in solid dosage forms, then chemical purity can be maintained, but flow properties deteriorate due to high aspect ratio rod-like crystal structure
Solution Approach 1:
The patent changes the physical state parameter of psilocybin from crystalline to amorphous form. This parameter change resolves the contradiction by eliminating the rod-like crystal structure that causes poor flow properties, while maintaining chemical purity through controlled amorphization processes and stabilization techniques during formulation.
Solution Approach 2:
The patent creates a composite material system by combining amorphous psilocybin with specific excipients and formulation components. This composite approach improves flow properties through the physical mixture characteristics while maintaining chemical stability through the synergistic effects of the formulation components.
2Reliability
If low dose psilocybin is used for therapeutic purposes, then therapeutic efficacy is improved, but content uniformity deteriorates in solid dosage forms
Solution Approach 1:
The patent changes the physical form parameter from crystalline to amorphous, which enables better dispersion and uniform distribution of low doses of psilocybin throughout the solid dosage form. This parameter change allows for improved content uniformity at low API loadings while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces specific excipients and formulation components as intermediaries that facilitate uniform distribution of low doses of psilocybin. These intermediaries act as carriers and dispersants that ensure consistent content uniformity even at low API concentrations, enabling reliable therapeutic delivery.
3Ease of manufacture
If commonly-used silica-containing excipients are used, then ease of manufacture is improved, but stability deteriorates due to discoloration and potency loss during storage
Solution Approach 1:
The patent extracts and removes silica-containing excipients from the formulation system. This extraction resolves the contradiction by eliminating the source of instability (silica) that causes discoloration and potency loss, while maintaining ease of manufacture by replacing silica with alternative excipients that do not compromise stability.
Solution Approach 2:
The patent converts the potential harm of using alternative excipients (which may be less commonly used) into a benefit by selecting excipients that provide both manufacturing convenience and enhanced stability. The formulation uses excipient combinations that prevent degradation pathways while maintaining ease of production.
Data Source
AI summary
The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.